NCT06994936View on ClinicalTrials.gov

An Open-label Study in Healthy Adults to Evaluate the Relative Bioequivalence of a Single-dose Administration of Sonelokimab Either by a Prefilled Syringe or an Autoinjector

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

June 5, 2025

Primary Completion Date

October 16, 2025

Study Completion Date

October 16, 2025

Conditions
Relative Bioequivalence
Interventions
DRUG

Sonelokimab

sonelokimab 120 mg administered subcutaneously via a PFS

DRUG

Sonelokimab

sonelokimab 120 mg administered subcutaneously via an AI

Trial Locations (1)

Unknown

Clinical Site, London

Sponsors
All Listed Sponsors
lead

MoonLake Immunotherapeutics AG

INDUSTRY

NCT06994936 - An Open-label Study in Healthy Adults to Evaluate the Relative Bioequivalence of a Single-dose Administration of Sonelokimab Either by a Prefilled Syringe or an Autoinjector | Biotech Hunter | Biotech Hunter